Navigation Links
While focusing on heart disease, researchers discover new tactic against fatal muscular dystrophy
Date:2/8/2009

NEW YORK (Feb. 8, 2009) Based on a striking similarity between heart disease and Duchenne muscular dystrophy, researchers at Columbia University Medical Center have discovered that a new class of experimental drugs for heart failure may also help treat the fatal muscular disorder.

At first glance, heart failure and the muscle-wasting Duchenne disease couldn't appear more dissimilar. Duchenne affects boys usually before the age of 6, destroying their muscle cells. The boys become progressively weaker through their teens and usually die in their twenties. In people without Duchenne, heart failure typically starts much later in life, robbing the heart's pumping ability in the 7th, 8th or 9th decade of life.

But the new study found that the muscle cells affected in both diseases have sprung the same microscopic leak that ultimately weakens skeletal muscle in Duchenne and cardiac muscle in heart failure. The leak lets calcium slowly seep into the skeletal muscle cells, which are damaged from the excess calcium in Duchenne. In people with chronic heart failure, a similar calcium leak continuously weakens the force produced by the heart and also turns on a protein-digesting enzyme that damages its muscle fibers.

Andrew Marks, M.D., the study's leader, hypothesized that a new class of experimental drugs developed at CUMC which he had designed to plug the leak in the heart could also work for Duchenne.

The drugs, when given to mice with Duchenne, dramatically improved muscle strength and reduced the number of damaged muscle cells.

"This was extremely exciting to us," says Dr. Marks, chair of the Department of Physiology & Cellular Biophysics and Clyde and Helen Wu Professor of Molecular Cardiology. "If it works in people, our drug won't be a cure, but it could slow the pace of muscle degeneration and extend the lives of people with Duchenne."

The study was published online Feb. 8 in Nature Medicine. Though the new drugs are not FDA-approved or currently available for Duchenne patients, a similar drug that was used in the Duchenne study is undergoing Phase I safety trials, and later this year trials will begin for heart failure.


'/>"/>

Contact: Alex Lyda
mal2133@columbia.edu
212-305-0820
Columbia University Medical Center
Source:Eurekalert

Related biology news :

1. U-M ballast-free ship could cut costs while blocking aquatic invaders
2. Fueling ethanol production while protecting water quality
3. Johns Hopkins researchers detect sweet cacophony while listening to cellular cross-talk
4. ESA satellites focusing on the Arctic
5. Abnormal fat metabolism underlies heart problems in diabetic patients
6. High blood pressure, low energy -- a recipe for heart failure
7. Human derived stem cells can repair rat hearts damaged by heart attack
8. Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction
9. Heart of Herschel to be presented to media
10. Minimally invasive heart surgery research wins NIH award
11. A step toward tissue-engineered heart structures for children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
(Date:1/6/2017)... Jan. 6, 2017  Privately-held CalciMedica, Inc., announced ... healthy volunteers of a novel calcium release-activated calcium ... pancreatitis. Acute pancreatitis, sudden painful ... disorder, but can be very serious.  In severe cases ... where extended hospital stays, time in the ICU ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" ... useful molecular diagnostic tests and pathology services, today ... purchase agreement with three  institutional investors to purchase ... in a registered direct offering.  In a concurrent ... to the same investors warrants to purchase 855,000 ...
(Date:1/21/2017)... Jan. 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... on the licensing, development and commercialization of innovative biopharmaceutical ... Best Company in North America ... award based on the FDA approval of three ... ENTYCE ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... , ... January 20, 2017 , ... The two newest ... treatment options for patients. Vironika, a spin out from The Wistar Institute, and Sanguis, ... lab space at 3624 Market Street. , Vironika is developing a treatment for ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo ... of Gen9, a pioneer in the synthesis and ... unique expertise in assembling pathway-length synthetic DNA into ... and capacity in the construction of new organism ... industries. "Gen9 was founded to significantly ...
Breaking Biology Technology: